Consistently with a central role of p53 in tumor suppression, a plethora of studies confirmed that impaired (in the case of loss-of-function) or aberrant p53 activity (in the case of gain-of-functions) [15,16,17], leads to increased predisposition to tumor development and hence the restoring of physiological p53 activity is regarded as a possible therapeutical strategy [5,6,18]. This evidence concerns the gene TP53 and neoplasm.